- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02338245
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab
Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 2A Design:
The Phase 2A part is an open-label, randomized, parallel group study using tumor size as its primary efficacy endpoint. Approximately 44 eligible patients will be randomized in a 1:1 ratio to receive either ASLAN001 400 mg orally twice daily (BID) or lapatinib 1250 mg orally once daily (QD), both on a background of capecitabine 1000 mg/m2 orally BID for Days 1-14 of a 21-day cycle. Radiological imaging to assess disease status will be performed at baseline and every 6 weeks until disease progression (as assessed by the Investigator). Patients who have not experienced disease progression after 12 weeks may continue to receive randomized therapy and will continue to have radiological scans every 6 weeks until disease progression.
Criteria to Proceed to Phase 2B:
In the absence of any safety or tolerability concerns, continuation to the Phase 2B part of the study will be primarily based on the statistical comparison of the percentage change in tumor size from baseline to Week 12 and a one-sided p-value <0.1 in favor of the ASLAN001-containing treatment arm would be supportive of continuation to Phase 2B.
Phase 2B Design:
The Phase 2B part of the study will continue to recruit if the pre-specified efficacy criteria are met in the Phase 2A part and if the tolerability of ASLAN001 in combination with capecitabine is considered acceptable.
The Phase 2B part is an open-label, randomized, parallel group study. In this part, approximately 160 patients will be randomized in a 1:1 ratio to receive either ASLAN001 400 mg BID or lapatinib 1250 mg QD, both in combination with capecitabine 1000 mg/m2 BID for Days 1-14 of a 21-day cycle.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Western Australia, Australia, 6000
- Australia
-
-
-
-
-
Hong Kong, Hong Kong
- Hong Kong
-
-
-
-
-
Seoul, Korea, Republic of, 110-744
- South Korea
-
Seoul, Korea, Republic of, 135-710
- South Korea
-
Seoul, Korea, Republic of, 137-701
- South Korea
-
Seoul, Korea, Republic of, 138-736
- South Korea
-
-
-
-
-
Christchurch, New Zealand, 8140
- New Zealand
-
Tauranga, New Zealand, 3143
- New Zealand
-
-
-
-
-
Bacolod City, Philippines
- Philippines
-
Dasmarinas, Philippines
- Philippines
-
-
-
-
-
Singapore, Singapore, 119074
- Singapore
-
Singapore, Singapore, 169610
- Singapore
-
-
-
-
-
KaohSiung, Taiwan, 833
- Taiwan
-
Taichung, Taiwan, 40447
- Taiwan
-
Taipei, Taiwan, 10449
- Taiwan
-
Taipei, Taiwan, 10507
- Taiwan
-
Taipei, Taiwan, 112
- Taiwan
-
Taipei, Taiwan, 114
- Taiwan
-
-
Taoyuan
-
Linkou, Taoyuan, Taiwan, 333
- Taiwan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with documented histological confirmation of breast cancer with HER 2 overexpression or gene amplification prior to study entry.
- Patients with HER 2-positive metastatic breast cancer that have failed on prior first line treatment with trastuzumab or who have progressed within 1 year of treatment with trastuzumab in adjuvant setting.
- Presence of at least one radiographically measurable disease (bone metastases and ascites are not considered measurable lesions).
- Patients of the respective country's legal age or older at the time of written informed consent.
- Patients with acceptable organ and hematological function
Exclusion Criteria:
- Patients with radiation treatment or major surgical procedures within 21 days prior to study entry.
- Patients with malabsorption syndrome, diseases significantly affecting gastrointestinal function, resection of the stomach or small bowel, or difficulty in swallowing and retaining oral medications.
- Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, diabetes, hypertension, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with any history of other malignancy unless in remission for more than 1 year. (Nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent is not exclusionary).
- Patients with symptomatic central nervous system metastasis and/or on systemic steroids or anticonvulsants within 3 months before the first dose of randomized therapy.
- Patients who are pregnant or breast-feeding.
- Patients who were previously treated with ASLAN001 and/or with lapatinib.
- Patients who have received more than 2 lines of any therapies in metastatic stage.
- Patients who have received any investigational drug (or have used an investigational device) within 21 days or received any antineoplastic monoclonal antibodies within a period of 5 half-lives before receiving the first dose of randomized therapy.
- Patients with unresolved or unstable serious toxicity from prior administration of another investigational drug and/or prior cancer treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm A
ASLAN001 + Capecitabine
|
ASLAN001 400mg BID
Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Other Names:
|
Active Comparator: Treatment Arm B
Lapatinib + Capecitabine
|
Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
Other Names:
Lapatinib 1250mg QD
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare the efficacy of ASLAN001 in combination with capecitabine, to lapatinib in combination with capecitabine in the percentage change from baseline tumor size at Week 12
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety for all metastatic breast cancer (MBC) subjects (Physical examination, body weight, vital signs, ECG parameter, hematology, clinical laboratory tests and Adverse Events)
Time Frame: estimated 2 years
|
Physical exam, body weight, vital signs (Blood pressure, respiratory rate and body temperateure), ECG parameter, hematology, clinical laboratory tests (clinical chemistry, coagulation and urinalysis) and Adverse Events (AEs)/ Serious Adverse Events (SAEs)
|
estimated 2 years
|
To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by PFS and tumor volume
Time Frame: Week 12
|
Week 12
|
|
To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by the Objective Response Rate (ORR), Duration of Response (DoR), and Overall Survival (OS)
Time Frame: 2 years
|
Composite outcome measures
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASLAN001-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on ASLAN001
-
ASLAN PharmaceuticalsCompletedStomach Neoplasms | Gastric Cancer | Gastric Neoplasms | Cancer of Stomach | Cancer of the StomachKorea, Republic of
-
ASLAN PharmaceuticalsCompletedCholangiocarcinomaTaiwan, Korea, Republic of, Singapore
-
National University Hospital, SingaporeUnknownAdvanced/ Metastatic Hepatocellular CarcinomaSingapore
-
ASLAN PharmaceuticalsCompletedGastric CancerEstonia, Hong Kong, Korea, Republic of, Lithuania, Malaysia, Singapore, Taiwan, Thailand
-
ASLAN PharmaceuticalsCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Biliary Tract CancerJapan
-
ASLAN PharmaceuticalsSyneos Health; bioRASI, LLC; CMIC Co, Ltd. JapanCompletedBiliary Tract CancerUnited States, Australia, China, Hong Kong, Hungary, Japan, Korea, Republic of, Poland, Singapore, Spain, Taiwan
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), Singapore; ASLAN PharmaceuticalsActive, not recruiting
-
National University Hospital, SingaporeUnknown
-
ASLAN PharmaceuticalsTerminatedBiliary Tract CancerTaiwan, Korea, Republic of, Singapore
-
ASLAN PharmaceuticalsCompletedSolid TumorTaiwan, Hong Kong